Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Imagin Medical Inc C.IME

Alternate Symbol(s):  IMEXF

Healthcare Medical Devices Diagnostics & Research
Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.


CSE:IME - Post by User

Imagin Medical Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Str8Shooter88on Nov 02, 2017 2:37pm
58 Views
Post# 26895958

RE:How's that research study coming along guys?

RE:How's that research study coming along guys?Keep on bashing Radar, but the price keeps on climbing = FAIL

radar17 wrote: You know, the one you tried to tell people would be done by December 2017 and that the company simply made a "typo" when they themselves, in a formal submission to the government, stated ...


Estimated Enrollment: 10
Anticipated Study Start Date: October 1, 2017
Estimated Study Completion Date: December 1, 2018
Estimated Primary Completion Date: October 1, 2018 (Final data collection date for primary outcome measure)

https://clinicaltrials.gov/ct2/show/NCT03058705?term=imagin+medical&rank=1


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested